Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study
Francesco Paciullo,
Loredana Bury,
Patrizia Noris,
Emanuela Falcinelli,
Federica Melazzini,
Sara Orsini,
Carlo Zaninetti,
Rezan Abdul-Kadir,
Deborah Obeng-Tuudah,
Paula G. Heller,
Ana C. Glembotsky,
Fabrizio Fabris,
Jose Rivera,
Maria Luisa Lozano,
Nora Butta,
Remi Favier,
Ana Rosa Cid,
Marc Fouassier,
Gian Marco Podda,
Cristina Santoro,
Elvira Grandone,
Yvonne Henskens,
Paquita Nurden,
Barbara Zieger,
Adam Cuker,
Katrien Devreese,
Alberto Tosetto,
Erica De Candia,
Arnaud Dupuis,
Koji Miyazaki,
Maha Othman,
Paolo Gresele
Affiliations
Francesco Paciullo
Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy
Loredana Bury
Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy
Patrizia Noris
Department of Internal Medicine, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy
Emanuela Falcinelli
Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy
Federica Melazzini
Department of Internal Medicine, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy
Sara Orsini
Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy
Carlo Zaninetti
Department of Internal Medicine, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy;PhD program in Experimental Medicine, University of Pavia, Pavia, Italy
Rezan Abdul-Kadir
Haemophilia Centre and Haemostasis Unit, The Royal Free Foundation Hospital and University College London, London, UK
Deborah Obeng-Tuudah
Haemophilia Centre and Haemostasis Unit, The Royal Free Foundation Hospital and University College London, London, UK
Paula G. Heller
Hematología Investigación, Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina;CONICET, Universidad de Buenos Aires, Instituto de Investigaciones Médicas -IDIM-, Buenos Aires, Argentina
Ana C. Glembotsky
Hematología Investigación, Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina;CONICET, Universidad de Buenos Aires, Instituto de Investigaciones Médicas -IDIM-, Buenos Aires, Argentina
Fabrizio Fabris
Clinica Medica 1 - Medicina Interna CLOPD, Dipartimento Assistenziale Integrato di Medicina, Azienda-Ospedale Università di Padova, Dipartimento di Medicina, Università di Padova, Padova, Italy
Jose Rivera
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguery Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
Maria Luisa Lozano
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguery Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
Nora Butta
Unidad de Hematología, Hospital Universitario La Paz-IDIPaz, Madrid, Spain
Remi Favier
Assistance Publique-Hôpitaux de Paris, Armand Trousseau Children’s Hospital, French Reference Centre for Inherited Platelet Disorders, Paris, France
Ana Rosa Cid
Unidad de Hemostasia y Trombosis, Hospital Universitario y Politecnico La Fe, Valencia, Spain
Marc Fouassier
Consultations d'Hémostase – CRTH, CHU de Nantes, Nantes, France
Gian Marco Podda
Medicina III, ASST Santi Paolo e Carlo, Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milan, Italy
Cristina Santoro
Hematology, Department of Translational and Precision Medicine, La Sapienza University of Rome, Rome, Italy
Elvira Grandone
Unità di Ricerca in Aterosclerosi e Trombosi, I.R.C.C.S. “Casa Sollievo della Sofferenza”, S. Giovanni Rotondo, Foggia, Italy;Ob/Gyn Department of the First I.M. Sechenov Moscow State Medical University, Moscow, The Russian Federation
Yvonne Henskens
Hematological Laboratory, Maastricht University Medical Centre, Maastricht, the Netherlands
Paquita Nurden
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguery Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
Barbara Zieger
Division of Pediatric Hematology and Oncology, Faculty of Medicine, Medical Center – University of Freiburg, Freiburg, Germany
Adam Cuker
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Katrien Devreese
Coagulation Laboratory, Department of Laboratory Medicine, Ghent University Hospital, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium
Alberto Tosetto
Hematology Department, S. Bortolo Hospital, Vicenza, Italy
Erica De Candia
Hemostasis and Thrombosis Unit, Insitute of Internal Medicine, Policlinico Agostino Gemelli Foundation, IRCCS, Rome, Italy;Institute of Internal Medicine and Geriatrics, Università Cattolica del Sacro Cuore, Rome, Italy
Arnaud Dupuis
Université de Strasbourg, Institut National de la Santé et de la Recherche Médicale, Etablissement Français du Sang Grand Est, Unité Mixte de Recherche-S 1255, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France
Koji Miyazaki
Department of Transfusion and Cell Transplantation Kitasato University School of Medicine, Sagamihara, Japan
Maha Othman
Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada
Paolo Gresele
Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy
Major surgery is associated with an increased risk of venous thromboembolism (VTE), thus the application of mechanical or pharmacologic prophylaxis is recommended. The incidence of VTE in patients with inherited platelet disorders (IPD) undergoing surgical procedures is unknown and no information on the current use and safety of thromboprophylaxis, particularly of low-molecular-weight-heparin in these patients is available. Here we explored the approach to thromboprophylaxis and thrombotic outcomes in IPD patients undergoing surgery at VTE-risk participating in the multicenter SPATA study. We evaluated 210 surgical procedures carried out in 155 patients with well-defined forms of IPD (VTE-risk: 31% high, 28.6% intermediate, 25.2% low, 15.2% very low). The use of thromboprophylaxis was low (23.3% of procedures), with higher prevalence in orthopedic and gynecological surgeries, and was related to VTE-risk. The most frequently employed thromboprophylaxis was mechanical and appeared to be effective, as no patients developed thrombosis, including patients belonging to the highest VTE-risk classes. Low-molecular-weight-heparin use was low (10.5%) and it did not influence the incidence of post-surgical bleeding or of antihemorrhagic prohemostatic interventions use. Two thromboembolic events were registered, both occurring after high VTE-risk procedures in patients who did not receive thromboprophylaxis (4.7%). Our findings suggest that VTE incidence is low in patients with IPD undergoing surgery at VTE-risk and that it is predicted by the Caprini score. Mechanical thromboprophylaxis may be of benefit in patients with IPD undergoing invasive procedures at VTE-risk and low-molecular-weight-heparin should be considered for major surgery.